synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
These findings are based on decades of data, and control for cohort groups; the data avoids the risk that the drops in happiness during midlife are due to populations' unique midlife experiences, like a war. The studies have also controlled for income, job status and parenting (as opposed to childlessness) to try to isolate the effects of age. Researchers found support for the notion of age changes inside the individual that affect happiness. This could be for any number of reasons. Psychological factors could include greater awareness of one's self and preferences; an ability to control desires and have more realistic expectations – unrealistic expectations tend to foster unhappiness; moving closer to death may motivate people to pursue personal goals; improved social skills, like forgiveness, may take years to develop – the practice of forgiveness seems linked to higher levels of happiness; or happier people may live longer and are slightly overrepresented in the elderly population. Age-related chemical changes might also play a role. Other studies have found older individuals reported more health problems, but fewer problems overall. Young adults reported more anger, anxiety, depression, financial problems, troubled relationships and career stress. Researchers also suggest depression in the elderly is often due largely to passivity and inaction – they recommend people continue to undertake activities that bring happiness, even in old age.
=== Movement of NAPLs in the saturated zone === In the saturated zone, the spaces between particles are filled with water. As such, a three-phase model of NAPL phase distribution is used in this zone, which excludes the gaseous phase. Once NAPLs reach the water table in the saturated zone, LNAPLs will float while DNAPLs will sink. Both LNAPLs and DNAPLs can remain in the water table for long periods of time, slowly dissolving and forming harmful chemical plumes; for this reason, remediation in the saturated zone is of particular importance to scientists.
1927 (Chemistry) Heinrich Otto Wieland — Constitution of bile acids and sterols and their connection to vitamins 1928 (Chemistry) Adolf Otto Reinhold Windaus — Constitution of sterols and their connection to vitamins 1939 (Chemistry) Adolf Butenandt and Leopold Ružička — Isolation and structural studies of steroid sex hormones, and related studies on higher terpenes 1950 (Physiology or Medicine) Edward Calvin Kendall, Tadeus Reichstein, and Philip Hench — Structure and biological effects of adrenal hormones 1965 (Chemistry) Robert Burns Woodward — In part, for the synthesis of cholesterol, cortisone, and lanosterol 1969 (Chemistry) Derek Barton and Odd Hassel — Development of the concept of conformation in chemistry, emphasizing the steroid nucleus 1975 (Chemistry) Vladimir Prelog — In part, for developing methods to determine the stereochemical course of cholesterol biosynthesis from mevalonic acid via squalene
Trinity admonishes Neo to run, but he stands his ground, having begun to believe that he may be the One. Neo and Smith draw guns and fire them empty, but are able to effortlessly dodge each other's fire. Neo skillfully engages Smith in hand-to-hand combat, almost seeming to be Smith's equal. In the end, Neo is briefly incapacitated and held by Smith as a subway train approaches, but at the last minute, he is able to get free and backflip up onto the platform, leaving Smith to be run over. However, the agent possesses the body of the conductor and emerges from the train. Neo, realizing that the agents' ability to possess other bodies makes this a fight he cannot win, flees the subway station. Pursued by Smith and his fellow agents, Neo is able to evade them and reach the location of the landline phone, just to be ambushed and fatally shot in the chest by Smith. Trinity, seeing Neo die in the real world while his mind is still in the Matrix, tells his evidently lifeless body that the Oracle had foretold that she would fall in love with the One. When kissed by Trinity, Neo is revived, finally fully emerging as the One. When the agents try to kill him again, Neo simply raises his hand, and the bullets freeze in mid-air, then drop harmlessly to the ground. It is then shown that he is able to perceive, interpret, and alter the computer code of the Matrix. Completely believing in his new-found powers, he effortlessly fends off agent Smith before forcing himself into the agent's body and destroying it from within. The other two agents quickly flee.
=== Arthritis === CCN1 is highly expressed in collagen-induced arthritis in rodents, and inhibition of CCN1 expression correlates with suppression of inflammatory arthritis. CCN1 is also found in articular cartilage from patients with osteoarthritis and appears to suppress ADAMTS4 (aggrecanase) activity, possibly leading to cartilage cell (chondrocyte) cloning.
Sources: en.wikipedia.org
For the use of hormone antagonists in cancer, see hormonal therapy (oncology) A hormone antagonist is a molecule, produced either synthetically or endogenously, that binds to a specific hormone receptor to block the effect or synthesis of that hormone. There are many types of hormone antagonists, such as gonadotropin-releasing hormone (GnRH) antagonists, estrogen antagonists, and androgen antagonists. Organisms may use hormone antagonists to modify the action of their hormone receptors. For example, ghrelin is a hormone that stimulates appetite and growth hormone release by activating the growth hormone secretagogue receptor (GHSR). LEAP2 was found to be a peptide hormone synthesized by the liver and small intestine that blocks the GHSR activation by ghrelin, thereby reducing appetite. Synthetically produced hormone antagonists can also be used as anticancer treatments for hormone-sensitive cancers like breast cancer and prostate cancer.
== Description == The ESG may be performed with slight variations by different physicians. It most commonly is performed using the Apollo ESG Device (formally Overstitch device). This device fits over a therapeutic double-channel endoscope to create a sutured row of stomach tissue. The tissue helix is advanced from the endoscope, put up against stomach tissue, and turned 2-4 rotations to access the gastric muscle layer. The helix is then retracted towards the scope, bringing the full-thickness acquired stomach tissue with it. Using the handle-operated needle driver, a needle attached to the suture wire is passed through the full-thickness tissue to the anchor exchange. This creates a full-thickness plication of stomach tissue. The needle is then passed back from the anchor exchange to the needle driver, and the process is repeated, threading the suture wire through each bite of stomach tissue. When enough full-thickness bites have been taken for a suture row, a cinch is passed through the scope over the suture. Typically, sutures are placed starting at the border of the antrum and gastric body at the incisura, then placed proximally up to the border of the gastric body and fundus. Each row of sutures can be a straight line or one of the variety of suture patterns reported in the literature, such as the "M," "Z," and "U" pattern as well as other novel patterns; nonetheless, to date, no suture pattern has been proven to be superior for weight loss. Regardless of suture pattern, creation of the ESG focuses on tissue imbrication along the greater curvature of the stomach.
== Mechanism == ATPase (also called FoF1-ATP Synthase) is a charge-transferring complex that catalyzes ATP to perform ATP synthesis by moving ions through the membrane. The coupling of ATP hydrolysis and transport is a chemical reaction in which a fixed number of solute molecules are transported for each ATP molecule hydrolyzed; for the Na+/K+ exchanger, this is three Na+ ions out of the cell and two K+ ions inside per ATP molecule hydrolyzed. Transmembrane ATPases make use of ATP's chemical potential energy by performing mechanical work: they transport solutes in the opposite direction of their thermodynamically preferred direction of movement—that is, from the side of the membrane with low concentration to the side with high concentration. This process is referred to as active transport. For instance, inhibiting vesicular H+-ATPases would result in a rise in the pH within vesicles and a drop in the pH of the cytoplasm. All of the ATPases share a common basic structure. Each rotary ATPase is composed of two major components: Fo/A0/V0 and F1/A1/V1. They are connected by 1-3 stalks to maintain stability, control rotation, and prevent them from rotating in the other direction. One stalk is utilized to transmit torque. The number of peripheral stalks is dependent on the type of ATPase: F-ATPases have one, A-ATPases have two, and V-ATPases have three. The F1 catalytic domain is located on the N-side (negative-side) of the membrane and is involved in the synthesis and degradation of ATP and is involved in oxidative phosphorylation.
The Rhodesian Front (RF) was a white supremacist political party in Southern Rhodesia, and, subsequently, the independent Rhodesia. Formed in March 1962 by white Rhodesians opposed to decolonisation and majority rule, it won that December's general election and subsequently spearheaded the country's Unilateral Declaration of Independence (UDI) from the Federation of Rhodesia and Nyasaland in 1965, remaining the ruling party and upholding white minority rule through the majority of the Bush War until 1979. Initially led by Winston Field, the party was led through most of its lifetime by co-founder Ian Smith. Following the end of the Bush War and the country's reconstitution as Zimbabwe, it changed its name to the Republican Front in 1981.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.